You are here

Once again, last November 2012 BIOIBERICA S.A. passed the inspection of the US FDA

30 Jan 2013

The US Authorities inspected the facilities related to the production of heparin in the plants of Palafolls and Probisa.

They focused on ensuring that our traceability system meets the standards currently required by the FDA, which apply to the documentary as well as to the production levels (from the slaughterhouses, to the control of our satellite plants until the final API).  The results were very satisfactory being the inspection a success. Once more, BIOIBERICA has demonstrated a remarkable quality level that allows us to be leaders in the production of heparin worldwide.

Related News

23 May 2024

A crucial initiative to prevent shortages of critical medicines in the European Union.

28 Sep 2021

The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by

4 Aug 2021
  • Bioiberica produces 20% of the world's Heparin API.
  • Heparin saves around a hundred million lives every year.
  • One out of every 5 doses of heparin administered in the world comes from Bioiberica.